Top

Published in:

01-12-2021 | Bevacizumab | Research

Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma

Authors: Takahiro Amano, Hideki Iijima, Shinichiro Shinzaki, Taku Tashiro, Shuko Iwatani, Mizuki Tani, Yuriko Otake, Takeo Yoshihara, Aya Sugimoto, Satoshi Egawa, Shinjiro Yamaguchi, Kazuo Kinoshita, Manabu Araki, Motohiro Hirao, Yuko Sakakibara, Satoshi Hiyama, Hiroyuki Ogawa, Koji Nagaike, Jun Murata, Masato Komori, Yorihide Okuda, Takashi Kizu, Yoshiki Tsujii, Yoshito Hayashi, Takahiro Inoue, Hidekazu Takahashi, Tsunekazu Mizushima, Eiichi Morii, Tetsuo Takehara

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the efficacy of bevacizumab for patients with mDJA.

Methods

This multicentre study included patients with histologically confirmed small bowel adenocarcinoma who received palliative chemotherapy from 2008 to 2017 at 15 hospitals. Immunostaining was performed for vascular endothelial growth factor-A (VEGF-A), TP53, Ki67, β-catenin, CD10, MUC2, MUC5AC, MUC6, and mismatch repair proteins.

Results

A total of 74 patients were enrolled, including 65 patients with mDJA and 9 with metastatic ileal adenocarcinoma. Patients with mDJA who received platinum-based chemotherapy with bevacizumab as first-line treatment tended to have a longer progression-free survival and overall survival than those treated without bevacizumab (P = 0.075 and 0.077, respectively). Multivariate analysis extracted high VEGF-A expression as a factor prolonging progression-free survival (hazard ratio: 0.52, 95% confidence interval: 0.30–0.91). In mDJA patients with high VEGF-A expression, those who received platinum-based chemotherapy with bevacizumab as a first-line treatment had significantly longer progression-free survival and tended to have longer overall survival than those treated without bevacizumab (P = 0.025 and P = 0.056, respectively), whereas no differences were observed in mDJA patients with low VEGF-A expression.

Conclusion

Immunohistochemical expression of VEGF-A is a potentially useful biomarker for predicting the efficacy of bevacizumab-containing chemotherapy for patients with mDJA.

Available only for authorised users

Delaunoit T, Neczyporenko F, Limburg PJ, Erlichman C. Pathogenesis and risk factors of small bowel adenocarcinoma: a colorectal cancer sibling? Am J Gastroenterol. 2005;100(3):703–10. https://doi.org/10.1111/j.1572-0241.2005.40605.x.CrossRefPubMed

Shenoy S. Primary small-bowel malignancy: update in tumor biology, markers, and management strategies. J Gastrointest Cancer. 2014;45(4):421–30. https://doi.org/10.1007/s12029-014-9658-z.CrossRefPubMed

Faivre J, Trama A, De Angelis R, Elferink M, Siesling S, Audisio R, et al. Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. Eur J Cancer. 2012;48(10):1417–24. https://doi.org/10.1016/j.ejca.2011.10.038.CrossRefPubMed

Khan K, Peckitt C, Sclafani F, Watkins D, Rao S, Starling N, et al. Prognostic factors and treatment outcomes in patients with small bowel adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience. BMC Cancer. 2015;15(1):15. https://doi.org/10.1186/s12885-015-1014-6.CrossRefPubMedPubMedCentral

Bailey AA, Debinski HS, Appleyard MN, Remedios ML, Hooper JE, Walsh AJ, et al. Diagnosis and outcome of small bowel tumors found by capsule endoscopy: a three-center Australian experience. Am J Gastroenterol. 2006;101(10):2237–43. https://doi.org/10.1111/j.1572-0241.2006.00749.x.CrossRefPubMed

Inoue Y, Hayashi M, Satou N, Miyamoto Y, Hirokawa F, Asakuma M, et al. Prognostic clinicopathological factors after curative resection of small bowel adenocarcinoma. J Gastrointest Cancer. 2012;43(2):272–8. https://doi.org/10.1007/s12029-011-9290-0.CrossRefPubMed

Imaoka H, Higaki N, Kumagi T, Miyaike J, Ohmoto M, Yamauchi K, et al. Characteristics of small bowel tumors detected by double balloon endoscopy. Dig Dis Sci. 2011;56(8):2366–71. https://doi.org/10.1007/s10620-011-1741-8.CrossRefPubMed

Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101(3):518–26. https://doi.org/10.1002/cncr.20404.CrossRefPubMed

Overman MJ, Hu CY, Kopetz S, Abbruzzese JL, Wolff RA, Chang GJ. A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease. Ann Surg Oncol. 2012;19(5):1439–45. https://doi.org/10.1245/s10434-011-2173-6.CrossRefPubMed

10.

Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Small bowel adenocarcinoma, version 1.2020, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2019;17(9):1109–33. https://doi.org/10.6004/jnccn.2019.0043.CrossRef

11.

Hirao M, Komori M, Nishida T, Iijima H, Yamaguchi S, Ishihara R, et al. Clinical use of molecular targeted agents for primary small bowel adenocarcinoma: a multicenter retrospective cohort study by the Osaka gut forum. Oncol Lett. 2017;14(2):1628–36. https://doi.org/10.3892/ol.2017.6290.CrossRefPubMedPubMedCentral

12.

Aydin D, Sendur MA, Kefeli U, Ustaalioglu BB, Aydin O, Yildirim E, et al. Evaluation of bevacizumab in advanced small bowel adenocarcinoma. Clin Colorectal Cancer. 2017;16(1):78–83. https://doi.org/10.1016/j.clcc.2016.04.013.CrossRefPubMed

13.

Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, et al. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: a single-center, open-label, phase 2 study. Cancer. 2017;123(6):1011–7. https://doi.org/10.1002/cncr.30445.CrossRefPubMed

14.

Takayoshi K, Kusaba H, Uenomachi M, Mitsugi K, Makiyama C, Makiyama A, et al. Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. Cancer Chemother Pharmacol. 2017;80(2):333–42. https://doi.org/10.1007/s00280-017-3371-0.CrossRefPubMed

15.

Legué LM, van Erning FN, Bernards N, Lemmens VEPP, de Hingh IHJT, Creemers GJ. Addition of bevacizumab to first-line palliative chemotherapy in patients with metastatic small bowel adenocarcinoma: a population-based study. Target Oncol. 2019;14(6):699–705. https://doi.org/10.1007/s11523-019-00681-1.CrossRefPubMed

16.

Overman MJ, Pozadzides J, Kopetz S, Wen S, Abbruzzese JL, Wolff RA, et al. Immunophenotype and molecular characterisation of adenocarcinoma of the small intestine. Br J Cancer. 2010;102(1):144–50. https://doi.org/10.1038/sj.bjc.6605449.CrossRefPubMed

17.

Rohrberg KS, Pappot H, Lassen U, Westman M, Olesen RK, Pfeiffer P, et al. Biomarkers in tissue from patients with upper gastrointestinal cancers treated with erlotinib and bevacizumab. Cancer Biol Ther. 2011;11(8):732–9. https://doi.org/10.4161/cbt.11.8.14889.CrossRefPubMed

18.

Oue N, Sentani K, Sakamoto N, Yasui W. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. Cancer Sci. 2015;106(8):951–8. https://doi.org/10.1111/cas.12706.CrossRefPubMedPubMedCentral

19.

Yao T, Tsutsumi S, Akaiwa Y, Takata M, Nishiyama K, Kabashima A, et al. Phenotypic expression of colorectal adenocarcinomas with reference to tumor development and biological behavior. Jpn J Cancer Res. 2001;92(7):755–61. https://doi.org/10.1111/j.1349-7006.2001.tb01158.x.CrossRefPubMedPubMedCentral

20.

Koga Y, Hirahashi M, Ohishi Y, Oda Y. Clinicopathological features and phenotypic classification of de novo-type colorectal carcinomas differ from those of colorectal carcinomas derived from flat adenomas. Pathol Int. 2019;69(6):331–40. https://doi.org/10.1111/pin.12803.CrossRefPubMed

21.

Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5(6):649–55. https://doi.org/10.1097/00000421-198212000-00014.CrossRefPubMed

22.

Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of Tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010.

23.

Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47. https://doi.org/10.1016/j.ejca.2008.10.026.CrossRefPubMed

24.

US Department of Health and Human Services: Common terminology criteria for adverse events (CTCAE) version 4.0. National Institutes of Health, National Cancer Institute 2009, 4(03).

25.

Toya Y, Endo M, Akasaka R, Urushikubo J, Gonai T, Asakura K, et al. Clinicopathological features and magnifying chromoendoscopic findings of non-ampullary duodenal epithelial tumors. Digestion. 2018;97(3):219–27. https://doi.org/10.1159/000485505.CrossRefPubMed

26.

Wakatsuki K, Yamada Y, Narikiyo M, Ueno M, Takayama T, Tamaki H, et al. Clinicopathological and prognostic significance of mucin phenotype in gastric cancer. J Surg Oncol. 2008;98(2):124–9. https://doi.org/10.1002/jso.21093.CrossRefPubMed

27.

Zhang MQ, Chen ZM, Wang HL. Immunohistochemical investigation of tumorigenic pathways in small intestinal adenocarcinoma: a comparison with colorectal adenocarcinoma. Mod Pathol. 2006;19(4):573–80. https://doi.org/10.1038/modpathol.3800566.CrossRefPubMed

28.

Zhang MQ, Lin F, Hui P, Chen ZM, Ritter JH, Wang HL. Expression of mucins, SIMA, villin, and CDX2 in small-intestinal adenocarcinoma. Am J Clin Pathol. 2007;128(5):808–16. https://doi.org/10.1309/JAF3KVGJHQCJ1QF9.CrossRefPubMed

29.

Aparicio T, Svrcek M, Zaanan A, Beohou E, Laforest A, Afchain P, et al. Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. Br J Cancer. 2013;109(12):3057–66. https://doi.org/10.1038/bjc.2013.677.CrossRefPubMedPubMedCentral

30.

Terada T. Malignant tumors of the small intestine: a histopathologic study of 41 cases among 1,312 consecutive specimens of small intestine. Int J Clin Exp Pathol. 2012;5(3):203–9.PubMedPubMedCentral

31.

Tajima Y, Shimoda T, Nakanishi Y, Yokoyama N, Tanaka T, Shimizu K, et al. Gastric and intestinal phenotypic marker expression in gastric carcinomas and its prognostic significance: immunohistochemical analysis of 136 lesions. Oncology. 2001;61(3):212–20. https://doi.org/10.1159/000055377.CrossRefPubMed

32.

Lee OJ, Kim HJ, Kim JR, Watanabe H. The prognostic significance of the mucin phenotype of gastric adenocarcinoma and its relationship with histologic classifications. Oncol Rep. 2009;21(2):387–93.PubMed

33.

Asghar U, Hawkes E, Cunningham D. Predictive and prognostic biomarkers for targeted therapy in metastatic colorectal cancer. Clin Colorectal Cancer. 2010;9(5):274–81. https://doi.org/10.3816/CCC.2010.n.040.CrossRefPubMed

Title: Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
Authors: Takahiro Amano
Hideki Iijima
Shinichiro Shinzaki
Taku Tashiro
Shuko Iwatani
Mizuki Tani
Yuriko Otake
Takeo Yoshihara
Aya Sugimoto
Satoshi Egawa
Shinjiro Yamaguchi
Kazuo Kinoshita
Manabu Araki
Motohiro Hirao
Yuko Sakakibara
Satoshi Hiyama
Hiroyuki Ogawa
Koji Nagaike
Jun Murata
Masato Komori
Yorihide Okuda
Takashi Kizu
Yoshiki Tsujii
Yoshito Hayashi
Takahiro Inoue
Hidekazu Takahashi
Tsunekazu Mizushima
Eiichi Morii
Tetsuo Takehara
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Bevacizumab
Cytostatic Therapy
Biomarkers
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08724-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2021

MicroRNA-1915-3p inhibits cell migration and invasion by targeting SET in non-small-cell lung cancer

Remote interventions to improve exercise behaviour in sedentary people living with and beyond cancer: a systematic review and meta-analysis

Real world duration of curative intent breast, colorectal, non-small cell lung, and prostate cancer treatment

Prognostic impact of tumor length in esophageal Cancer: a systematic review and Meta-analysis

“Randomized trial of physical activity on quality of life and lung cancer biomarkers in patients with advanced stage lung cancer: a pilot study”

Urban-rural disparity in cancer mortality and changing trend in Tianjin, China, during 1999 and 2016

Keynote webinar | Spotlight on antibody–drug conjugates in cancer